IP Library › Granted Patent US 8,637,530
Granted Patent B2
US 8,637,530 · App. 13/346,234 · Granted Jan 28, 2014

8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals

Inventors: Waldemar Pfrengle (Biberach, DE); Peter Sieger (Mittelbiberach, DE)
Assignee: Boehringer Ingelheim International GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,530
App. No.
13/346,234
Granted
Jan 28, 2014
Kind
B2
Abstract

The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.

Claims (18)

1. A compound which is the monohydrochloride or dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

2. The compound of claim 1 , which is the monohydrochloride salt.

3. A pharmaceutical composition comprising a compound of claim 1 , and an excipient.

4. The pharmaceutical composition of claim 3 , wherein the compound is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

5. A method for treating Type II diabetes mellitus or obesity in a mammal comprising administering to a mammal in need thereof a compound which is the monohydrochloride or dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

6. The method of claim 5 , wherein the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is administered.

7. The compound of claim 1 , which is the dihydrochloride salt.

8. The pharmaceutical composition of claim 3 , wherein the compound is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

9. The method of claim 5 , wherein the compound administered is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

10. The compound of claim 1 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

11. The composition of claim 3 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

12. The method of claim 5 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

13. The compound of claim 10 , which is the monohydrochloride salt.

14. The compound of claim 10 , which is the dihydrochloride salt.

15. The composition of claim 11 , wherein the compound is the monohydrochloride salt.

16. The composition of claim 11 , wherein the compound is the dihydrochloride salt.

17. The method of claim 12 , wherein the compound is the monohydrochloride salt.

18. The method of claim 12 , wherein the compound is the dihydrochloride salt.

Priority Claims (1)
DE 10 2005 035 891 · Jul 30, 2005 · national
Continuity (2)
Division 11460996 · Jul 30, 2006
Related Publication 20120142712A1 · Jun 7, 2012